MMSI Merit Medical Systems, Inc.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Over the past six months, Merit Medical Systems has been a great trade, beating the S&P 500 by 9.1%. Its stock price has climbed to $85.50, representing a healthy 25.5% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

In August 2026, Merit Medical Systems announced that Sheri Lewis would join as Executive Vice President of Global Operations, bringing three decades of global manufacturing and supply chain experience from SkinHealth Systems, Avantor, Medtronic, and Honeywell, while long-time operations leader Mr. Peterson shifted to a Senior Advisor role through March 2027 to support continuity. This leadership transition highlights Merit's focus on strengthening global operations and supply chain...

Why this leadership change at Merit Medical Systems matters for investors Merit Medical Systems (MMSI) recently announced that Sheri Lewis will become Executive Vice President of Global Operations on August 31, 2026, with long time operations leader Mr. Peterson shifting to a Senior Advisor role. For you as an investor, this type of operational leadership change can influence how effectively the company runs its global manufacturing footprint and manages costs. It can also shape how resilient...

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.

Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.

COO vs. MMSI: Which Stock Is the Better Value Option?

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Merit Medical Systems (NASDAQ:MMSI) is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event. Parra said the company remains “hyper-focused” on execut

Merit Medical Systems (NASDAQ:MMSI) is preparing its next long-range plan as the medical-device company works through a leadership transition, updates its reporting structure and seeks to build on recent revenue and margin momentum. Speaking at Bank of America’s virtual SMID Cap event, Chief Financ

Revenue beat guidance while operating margins expanded 142 basis points year over year.

COO vs. MMSI: Which Stock Is the Better Value Option?

Medical device company Merit Medical Systems (NASDAQ:MMSI) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates.

Merit Medical Systems (MMSI) is back in focus after releasing second quarter 2026 results and raising its full year outlook, with updated guidance reflecting stronger than expected performance in the first half. See our latest analysis for Merit Medical Systems. Merit Medical Systems’ recent earnings release and higher 2026 guidance have coincided with building momentum, with a 30 day share price return of 22.4% and a 90 day share price return of 37.1%, while the 1 year total shareholder...

Merit Medical Systems (NASDAQ:MMSI) reported second-quarter 2026 revenue of $418.8 million, up 10% on a GAAP basis and 9% on a constant-currency basis from a year earlier, as broad-based demand across its Foundational and Therapeutic product categories lifted organic growth to its strongest quarterl

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

Moby summary of Merit Medical Systems, Inc.'s Q2 2026 earnings call

Merit Medical Systems Inc (MMSI) delivers 9% constant currency organic growth and 18% EPS increase, prompting upward revision of full-year 2026 outlook.

Merit Medical (MMSI) delivered earnings and revenue surprises of +23.96% and +3.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Merit Medical (MMSI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Medical device company Merit Medical Systems (NASDAQ:MMSI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates.

MMSI vs. WST: Which Stock Is the Better Value Option?